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The purpose of this study was to develop a reservoir-type transdermal delivery system for isosorbide 
dinitrate (ISDN). The developed patch consisted of five layers from bottom to top, namely, a temporary 
liner, an adhesive layer, a rate-controlling membrane, a reservoir and a backing. The effects of chemical 
penetration enhancers, reservoir materials and rate-controlling membranes on the release behaviour of 
ISDN from the transdermal patch were studied, and the in vitro release of ISDN from the developed patch 
was studied and compared with the commercially available ISDN patch. The results showed that there 
was no significant difference in permeation rates between the developed reservoir-type patch and the 
commercially available ISDN patch (p > 0.05). Moreover, the cumulative release ratio of the commercially 
available ISDN patch in 48 h was up to 89.8%, whereas the developed patch was only 34.9%, which 
meant the sustained release time of the developed patch was much longer than the commercially available 
ISDN patch, and would promote the satisfaction of the patient.
Uniterms: Isosorbide dinitrate/transdermal drug-delivery system. Transdermal patches/in vitro release. 
Transdermal patches/sustained release. Controlling membrane/drugs release rate. Skin penetration/
drugs release.
O objetivo do presente estudo foi desenvolver um sistema de liberação transdérmico do tipo reservatório 
para o dinitrato de isossorbida (ISDN, abrevitura em Inglês). A formulação transdérmica desenvolvida 
constou de cinco camadas de baixo para cima, ou seja, um revestimento temporário, uma camada adesiva, 
uma membrana controladora da taxa de liberação, um reservatório e um reforço. Estudaram-se os efeitos 
dos potenciadores de penetração química, materiais do reservatório e membranas de controle da taxa de 
liberação no comportamento da formulação transdérmica de dinitrato de isossorbida. A liberação in vitro 
da formulação transdérmica de dinitrato de isossorbida desenvolvida foi estudada em comparação com 
a formulação de dinitrato de isossorbida disponível comercialmente. Os resultados mostraram que não 
existem diferenças significativa nas taxas de permeação entre o tipo de reservatório desenvolvido e o de 
dinitrato de isossorbida desenvolvido comercialmente (p>0,05). Ademais, a taxa de liberação cumulativa 
da formulação de dinitrato de isossorbida disponível comercialmente em 48 horas foi de até 89,8% e a da 
formulação desenvolvida, de apenas de 34,9%, o que provou que a liberação sustentada da formulação 
desenvolvida foi muito maior do que a de dinitrato de isossorbida desenvolvida comercialmente, o que 
promoveria a satisfação do paciente.
Unitermos: Dinitrato de isossorbida/Sistema de liberação transdérmico. Formulações transdérmicas/
liberação in vitro. Formulações transdérmicas/liberação sustentada. Membrana de controle/taxa de 
liberação de fármacos. Penetração cutânea/liberação de fármacos.
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INTRODUCTION
Transdermal-patch technology has advanced 
tremendously since the first scopolamine patch was 
introduced into the market in 1979. It can be attributed 
to today’s advanced patch-making technology, through 
which nearly a billion patches are manufactured every 
year (Prausnitz, Langer, 2008). These transdermal patches 
are classified into three types: drug in adhesive (the drug 
is directly dispersed into the adhesive polymer), reservoir 
(consists of a drug reservoir between a backing membrane 
and rate-controlling membrane, with a skin-contacting 
adhesive layer) and matrix (consists of a drug reservoir 
in the centre with a peripheral adhesive ring around the 
edges) (Tan, Pfister, 1999; Subedi et al., 2010).
Isosorbide dinitrate (ISDN) is commonly used for 
the therapy of stable angina pectoris and is traditionally 
administrated via oral or sublingual routes. However, loss 
of consciousness appears in patients when angina pectoris 
breaks out, and thus it is difficult for patients to take the 
medicine by themselves. Additionally, administrated 
orally ISDN has low bioavailability, owing to its high 
first-pass metabolism in the gastrointestinal tract and 
liver. Moreover, the critical point of anti-anginal therapy 
depends, to a certain extent, on the ability of the drug to 
produce an immediate effect (Johnson, Gladigau, Schnelle, 
1981; Fung, 1985; Taylor et al., 1985). Thus, transdermal 
delivery may be an appropriate administration route for 
ISDN. 
Among the ISDN transdermal patches designed 
and reported previously, the drug-in-adhesive patches are 
the simplest and the most commonly used design. Zhao 
et al. (2007) developed single-layer drug-in-adhesive 
transdermal patches, in which the adhesive layer not 
only serves as an adhesion layer to the skin, but also 
is responsible for the release of the drug. The in vitro 
release results show that the release kinetics of ISDN is a 
first-order process, suggesting that the outwards moving 
of ISDN from the adhesive is associated with a passive 
diffusion process.
Drug release from a drug-in-adhesive patch depends 
directly upon the drug concentration in the patch and 
follows first-order kinetics. However, reservoir-type 
transdermal drug delivery could be observed the zero-
order kinetics. The rate controlling membrane, as a most 
important component in the reservoir-type transdermal 
patch, was responsible for controlling drug delivery. 
The rate-controlling membranes reported in previous 
publications included ethyl cellulose (Lewis, Pandey, 
Udupa, 2006), collagen and chitosan (Thacharodi, Rao, 
1996), ethylene-vinyl acetate (EVA) (Shen et al., 2013) 
and acrylate polymers (Zhan et al., 2007a, b, c). Previous 
work in our lab has proven that acrylate polymers, as a 
new type of rate-controlling membranes, could control 
clonidine HCl solution release with zero order (Zhan et 
al., 2007a, b, c). But, such film-like acrylate polymers 
have not been applied in the production of patches to date.
The aim of this study was to develop a reservoir-
type transdermal patch of ISDN with acrylate polymer 
as the rate-controlling membrane, which could keep drug 
release at a constant rate for at least 48 h. The effects of 
chemical penetration enhancers, reservoir materials and 
rate-controlling membranes on the release behaviour 
of ISDN permeation across the transdermal patch were 
studied. Consequently, the in vitro release of ISDN from 
such a patch was studied in comparison to commercially 
available ISDN patches.
MATERIAL AND METHODS
Material
2-Hydroxy-3-phenoxypropylacrylate (marked A), 
4-hydroxybutyl acrylate (marked B), diethyl maleate 
(marked C1), dibutyl maleate (marked C2) and 2-methyl-
2-nitropropyl methacrylate (marked C3) were purchased 
from Aldrich (USA). Benzoyl peroxide, ethyl cellulose 
(EC), polyethylene glycol 400 (PEG400), methylene 
chloride, ethanol absolute, oleic acid, urea, propylene 
glycol and polyvinyl alcohol 17-88 (PVA17-88) were 
purchased from National Medicine Corporation (CHN). 
Isosorbide dinitrate (ISDN) was purchased from 
Shanghai Yuanji Chemical Co., Ltd. Polyvinyl alcohol 
05-88 (PVA05-88) was purchased from Shanghai Jin Wei 
Trading Co., Ltd. Polyvinyl pyrrolidone K90 (PVP K90) 
was presented by Boai New Kaiyuan Pharmaceutical 
Co., Ltd. Methanol was of HPLC grade. Frandol® tape 
was purchased from Yamanuchi Pharm (JP) (40 mg in 
40 cm2). All other chemicals were of reagent grade and 
used as received.
Fabrication of a reservoir-type transdermal patch 
of ISDN
The structure of the transdermal patch consisted of 
five layers, namely, a temporary liner, an adhesive layer, 
a rate-controlling membrane, a reservoir and a backing 
(Figure 1). First, the adhesive solution was coated onto the 
temporary liner (3M, ScotchpakTM 1022) and was allowed 
to dry completely. Then, a polyacrylate membrane, as a 
rate-controlling membrane, was pressed over the adhesive 
layer. Then, the reservoir layer was pressed onto the rate-
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controlling membrane. Last, the polyester film laminate 
(3M, ScotchpakTM 9732), as a backing layer, covered the 
reservoir. The temporary liner and the backing layer were 
then heat-sealed and cut to the appropriate sizes. The patch 
was stored in a sealed aluminium pouch to minimise the 
loss of solvent. 
Preparation of the pressure-sensitive adhesives 
(PSAs)
PSAs with ISDN (0.96 g PVP K90, 0.18 g PEG400, 
0.06 g gelatin and 100 mL deionised water) were put 
into a three-necked boiling flask and stirred at 80 ºC 
until the solid reagents dissolved completely; this was 
then refluxed for 2 h 120 ºC to decrease the strength 
and viscosity of the gelation solution. The solution was 
cooled before adding 0.06 g ISDN and stirring until the 
ISDN was homogeneously dispersed. The mixture was 
cast onto the temporary liner in 200 cm2 areas and dried at 
60 ºC; 0.3 mg of ISDN per cm2 was obtained in the PSAs. 
The preparation process of PSA without ISDN was 
the same procedure, except no ISDN was added.
Preparation of the rate-controlling membranes
We used a previously reported method that had 
already been used in our lab to prepare three rate-
controlling membranes (Figure 2), that is, membrane M1 
made of monomers A, B and C1 (Zhan et al., 2007a), 
membrane M2 made of monomers A, B and C2 (Zhan et 
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FIGURE 2 - The structure of acrylate monomers.
FIGURE 1- The construction of the ISDN transdermal patch.
al., 2007b), and membrane M3 made of monomers A, B 
and C3 (Zhan et al., 2007c). The ratio of the monomers in 
each membrane was 4:4:2 (w/w/w). We used 3% (w/w) 
benzoyl peroxide as the photo-initiator reagent. The 
mixture of monomers with the photo-initiator was treated 
under UV light in UV-curing equipment (Beijing Aishibo 
Machinery Electronic Equipment Centre, China). The 
thickness of all resultant membranes was 14µm. 
Preparation of the drug reservoir
ISDN in EC reservoir: 5.1 g of EC were completely 
dissolved in methylene chloride, and then 0.54 g of ISDN 
was added and dissolved. The mixed solution was casted 
onto a glass plate with 200 cm2 areas; the plate was then 
put in an air-conditioned chamber at room temperature for 
24 h under 60–70% relative humidity in order to evaporate 
the methylene chloride, and a 2.7 mg ISDN layer (per cm2 
EC) was formed. The drug reservoir layer was separated 
carefully from the glass plate, and then pressed tightly on 
the rate-controlling membrane.
ISDN in PVA reservoir: 5.1 g of a PVA mixture 
(PVA0588/ PVA1788=1:2.5 mol/mol) was dissolved in 
water/ethanol (1:1 v/v) solution, and then 0.54 g of ISDN 
was added and dissolved. The mixed solution was casted 
onto a glass plate with 200 cm2 areas, and then the plate 
was put in an oven (Hanzhou Huier Equipment Co., Ltd., 
China) at 65 °C for 24 h in order to evaporate H2O and 
ethanol, and a 2.7 mg ISDN layer (per cm2 PVA) was 
formed. The drug reservoir layer was carefully separated 
from the glass plate and tightly attached to the rate-
controlling membrane.
Preparation of the drug reservoir containing 
penetration enhancer
The preparation of the drug reservoir with a 
penetration enhancer followed the same procedure as the 
preparation of the PVA reservoir layer. When ISDN was 
dissolved in PVA solution, 15% (w/w) oleic acid, 15% 
(w/w) 1,2-propylene glycol and 5% (w/w) urea were used 
as penetration enhancers, which were added into the PVA 
reservoir layer, stirred and homogeneously dispersed in 
the reservoir. 
Characterisation of optimised formulation
Thickness
The patch thickness was measured using a digital 
meter (Shanghai Measuring and Cutting Tools Factory, 
China) at five different places. The average and standard 
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deviation of five readings were calculated for three batches 
of the optimised formulation with an area of 1 cm2.
Weight
Three different patches from three batches, each 
with an area of 1 cm2, were weighed individually, and the 
average weight and standard deviation was calculated.
Drug content
Three individual patches from three batches, each 
with an area of 1 cm2, were cut into small pieces and 
dissolved in 100 mL of methanol/water solution (54:46 
v/v). The solution was filtered, diluted suitably and 
measured by HPLC.
Skin for permeation studies
Hairless rat skin was used to evaluate the effects of 
penetration enhancers on the permeation and to evaluate 
the permeation of ISDN release from the optimised 
developed patch. The skin was isolated from hairless 
rats (male, 8-10 weeks old and 350-400 g in weight) that 
were obtained from Slac Lab. Animal (Shanghai, China). 
All studies were performed as per the protocol approved 
by the Institutional Animal Care and Use Committee 
(IACUC) at Shanghai Jiaotong University. Hairless 
rats were euthanised by carbon dioxide asphyxiation 
prior to the permeation experiment and its abdominal 
skin was carefully excised using scissors and forceps. 
The underlying subcutaneous fat was removed from 
the excised skin and the thus-obtained abdominal skin 
(ca. 1 mm thick) was used for permeation experiments.
Permeation studies
Permeation experiments were carried out to 
evaluate the rate-controlling membrane, the drug 
reservoirs, the penetration enhancers and the integral 
developed patch. The tested component was cut into 
appropriate sizes and mounted on a modified Franz 
diffusion assembly (Ng et al., 2010) produced at 
Huanghai Medicine & Drug Testing Instruments (China). 
When the tested component was the integral developed 
patch, the temporary line should be removed, and the 
dermis side of the skin faced the receptor compartment. 
The effective diffusion area was 0.785 cm2. The receptor 
compartment was filled with 25.0 ± 0.1 mL of PEG400 
and normal saline in the volume ratio of 4:6, and the 
sink conditions were maintained during the permeation 
experiment. The receptor medium was maintained at 
37.0 ± 0.1 ºC and stirred constantly at 200 ± 2 rpm. At 
pre-determined time intervals 0.5, 1.5, 3, 4.5, 6.5, 8.5, 
10.5, 12 and 24 h, 200 μL of the receptor solution was 
taken out and replaced with an equal volume of fresh 
receptor medium. The samples were analysed by HPLC.
HPLC analysis of ISDN
The HPLC system (Waters, USA) consisted of a 
1525 binary pump, a 717 plus auto-sampler and a 2487 
dual-wavelength UV absorbance detector. Data acquisition 
and processing were dealt with by Waters Empower 
professional software. The mobile phase was a mixture 
of methanol and water in the volume ratio of 54:46. The 
mobile phase was filtered through a 0.45 mm porosity filter 
and degassed. The liquid chromatograph was equipped 
with a 80 Å, 5 µm, 4.6 mm×250 mm C18 column (Agilent 
Zorbax Extend) with a flow rate of 1 mL/min. The volume 
of each injected sample was 20 µL, the wavelength of the 
UV detector was set at 220nm, and the run time was 15 min 
(USP 32, 2009).
Validation studies of the HPLC method
Linearity and range
A stock solution of ISDN (1 mg/mL) was prepared 
in the mobile phase. Seven standard solutions (1 to 
100 μg/mL) were diluted from this stock solution using 
the mobile phase for the assessment of linearity. The peak 
areas for ISDN (n=5) versus concentrations were plotted 
and fitted to be linear over the entire concentration range.
Accuracy
The accuracy was determined by recovery studies. 
The samples were analysed at three concentrations of 5, 25 
and 100 μg/mL by the proposed method. The experiments 
were conducted in triplicate.
Precision
The intra-day variability was checked at three time 
points on the same day, and the inter-day variability was 
checked on three consecutive days. The samples were 
analysed at three concentrations of 5, 25 and 100 μg/mL 
by the proposed method. The results were expressed 
as the percent relative standard deviation (% RSD) of 
concentration. 
Specificity
A set of sample solutions were prepared to ascertain 
the specificity of the method. The blank solution was the 
mobile phase, the standard solution contained 50 μg/mL 
ISDN dissolved in the mobile phase, the drug substance 
solution was 50 μg/mL ISDN dissolved in the receptor 
medium (PEG400: normal saline = 4: 6 v/v), placebo 
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1 solution contained PSAs (50 μg/mL PVP K90 and 
50 μg/mL gelation dissolved in the receptor medium and 
then filtered), placebo 2 solution contained penetration 
enhancers (50 μg/mL oleic acid, 50 μg/mL 1,2-propylene 
glycol and 50 μg/mL urea dissolved in the receptor 
medium and then filtered) and placebo 3 was for the 
drug reservoir (50 μg/mL EC, 50 μg/mL PVA0588 and 
50 μg/mL PVA1788 dissolved in the receptor medium and 
then filtered).
Detection and quantitation limits
The LOD (limit of detection) and LOQ (limit of 
quantitation) were defined as the concentrations that 
yielded a measured peak with a S/N (signal-to-noise ratio) 
of 3 and 10, respectively.
Test of sink conditions
Assuring the sink conditions in the in vitro 
release experiment is very important. According to the 
requirements of the sink conditions, the volume of the 
receptor medium was generally greater than 5-10 times 
that of the saturation point of ISDN in this medium. Thus, 
the saturated solubility of ISDN in the receptor medium 
needed to be quantified. ISDN was added to the flask with 
25.0 mL of the receptor medium and sonicated for 24 h at 
20 °C until no more solid dissolved. The saturated solution 
was filtered and then measured by HPLC. 
Data analysis
The cumulative amount of ISDN was calculated as 
follows:
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where Q is the cumulative amount of the drug (μg/cm2), 
V is the receptor solution volume (mL), Vi is the sample 
volume (mL), Cn and Ci are the drug concentrations in 
the receptor cells and the concentration of the extraction 
samples (μg/mL), respectively, and A is the transporting 
area (cm2). 
The cumulative drug amount (Qt, μg/cm2) was 
plotted versus time (T, h). The slope of the linear portion 
of the plot was presented as the permeation rate (Jss, 
μg/cm/h). The intercept on the x-axis was taken as the 
lag time (TL, h). All of the release experiments were 
repeated three times from independent batches, and mean 
values of the permeation rates with standard deviations 
were calculated. Student’s t-test and analysis of 
variance (ANOVA) were used to statistically determine 
significant differences. The p value used in this study 
was 0.05.
RESULTS AND DISCUSSION
Method validation of HPLC
Linearity and range
The calibration curve for ISDN obtained from the 
developed HPLC method was displayed in Figure 3. As 
shown, the peak areas of the drugs were obtained to be 
strictly linear in the concentration range of 1 to 100 μg/mL; 
the correlation coefficient value was 0.9999.
Accuracy
The percentage recoveries of the three concentrations 
from low to high were found to be 102.07 ± 0.63, 
102.75 ± 0.21 and 99.78 ± 0.32%, respectively, which 
confirms that the method was accurate.
Precision
The % RSD of the developed intra-day HPLC 
method was 0.44 ± 0.28, and the % RSD of inter-day 
method was 0.52 ± 0.22, which suggests the excellent 
precision of the developed HPLC method.
Detection and quantitation limits
The LOD and LOQ values were found to be 100 and 
350 ng/mL, respectively.
Specificity
The method specificity was assessed by comparing 
the chromatograms obtained from the sample solutions 
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FIGURE 3 – Calibration curve for ISDN from the HPLC method.
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(Figure 4); the retention time of ISDN observed from the 
HPLC was 6.147 min. 
Evaluation of sink conditions
The solubility of ISDN in the PEG400/normal saline 
solution (4:6 v/v) at 20 °C was 1.85 ± 0.03 mg/mL (n=3). The 
solubility of ISDN in water at 20 °C was 1.45 ± 0.01 mg/mL 
(n=3). The solubility of ISDN in PEG400/normal saline 
solution increased slightly compared to its solubility in 
water. The highest drug content in our research was 5 mg 
(the concentration in donor compartment: 5 mg/mL, 
volume: 1 mL), and the receptor media volume was 25 mL; 
the concentration was 0.2 mg/mL if 5 mg of ISDN was 
completely dissolved in 25 mL of media. Thus, the receptor 
media volume was nine times greater than the saturation 
point and the sink conditions were achieved during the 
permeation experiment. In fact, other researchers also used 
water as the receptor media for the purpose of simulating 
a human physiological environment (Zhao et al., 2007).
Effect of the rate-controlling membrane on the 
permeation
To screen a suitable rate-controlling membrane, 
different concentrations of ISDN in 1,2-propylene glycol 
solution (1.0, 2.0, 3.0, and 5.0 mg/mL) were used as donor 
solutions in the modified Franz cells with a volume of 
1 mL. The release behaviours of ISDN across different 
rate-controlling membranes were studied over 24 h. It 
was found that the rate-controlling membrane marked M1 
showed the highest value of permeation rates under the 
same drug-donor concentration, as shown in Figure 5. This 
result could be explained by the pore sizes of membrane 
M1, which was fabricated randomly by polymer chains. 
As polyacrylates are non-degradable polymers, they 
are controlled drug molecules across the pores in the 
membrane instead of degradation, erosion or dissolution of 
the polymer. The shorter side chain of monomer C1 would 
occupy the pore’s inner space less compared with C2 and 
C3, as a result of the drug molecules release across the 
membrane M1 more easily. Membrane M1 also showed 
higher permeation rates compared to M2 and M3 when 
the tested drug was clonidine HCl (Zhan et al., 2007a,b,c).
 
Effect of the drug reservoir on the permeation
Two types of drug reservoir, EC and PVA, were 
designed. The permeation of ISDN from the drug reservoir 
across rate-controlling membrane M1 was studied. Table I 
FIGURE 4 – Chromatograph from HPLC obtained from different 
sample solutions.
TABLE I - The permeation of ISDN releasing from the drug reservoir across M1
Formulation Reservoir Jss (μg/cm2/h)
Cumulative 
amount of 
release at 24 h 
(μg)
Correlation 
factor (r2) TL (h)
Cumulative 
ratio of release 
at 24 h (%)
F1 EC 1.7 ± 0.1 30.7 ± 1.1 0.9967 8.1 1.3 ± 0.03
F2 PVA 43.2 ± 1.8 957.2 ± 54.3 0.9817 - 40.1 ± 0.8
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FIGURE 5 - The permeation of ISDN through different rate-
controlling membranes.
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TABLE II - Physicochemical properties of penetration enhancers
Penetration 
enhancers
Molar mass 
(g/mol)
logP*
Oleic acid 282.46 7.7
Propylene glycol 76.05 –0.92
Urea 60.06 –2.11
* Experimental data
TABLE III - Permeation of ISDN in PVA reservoir with different penetration enhancers transporting through the M1
Formulation Penetration enhancer Jss (μg/cm2/h)
Cumulative amount 
of release at 24 h 
(μg)
Correlation 
factor (r2)
Cumulative ratio of 
release at 24 h (%)
F3 15% Oleic acid 44.5 ± 0.7 1040.4 ± 53.9 0.9942 39.4 ± 2.2
F4 15% 1,2-Propylene glycol 44.3 ± 0.5 1000.1 ± 19.0 0.9917 40.4 ± 0.6
F5 5% Urea 44.8 ± 0.8 1017.9 ± 54.1 0.9889 41.1 ± 1.6
shows that PVA had a better permeation compared with 
EC, which increased the permeation rate 25.4 fold, a 
31.1-fold cumulative release after 24 h, and a 30.8-fold 
cumulative ratio of release at 24 h. Moreover, ISDN 
releasing from PVA were not observed in the lag time, but 
EC had serious lag time of 8.1 h. So, the PVA was chosen 
to perform latter experiment.
Effect of the penetration enhancers on the 
permeation
To screen the penetration enhancers, three 
penetrations covering a broad range of lipophilicity values 
(logP values of penetrations amounted to –2.11, –0.92 and 
7.7 for urea, propylene glycol and oleic acid, respectively) 
(Table II) (Yangali-Quintanilla et al., 2009) were chosen 
to investigate the impact of the partitioning characteristic 
of penetrations on the permeation. The weight ratio of 
the penetration enhancers were reported in a previously 
published paper (Halina; Krzysztof; Stanislaw, 2000; 
Chen et al., 1992). The release behavior of ISDN in the 
PVA reservoir with the penetration enhancer transporting 
across the M1 was evaluated (Table III). It was found that 
there was no significant promotion on the permeation 
rates among the groups of drug reservoirs with or without 
penetration enhancers (p > 0.05) (Table IV).
Although the penetration enhancers had no effects 
when the drug transported across the rate-controlling 
membrane, M1, it was well known that the penetration 
enhancers had serious effects on the skin in general. To 
further illustrate how the penetration enhancers affected 
the permeation rates, the release behaviours of ISDN in 
the formulation groups F2, F3, F4 and F5 transporting 
across the rats’ ex-vivo skin were studied. It was found 
that formulation F5, of which urea was the penetration 
enhancer, had a higher permeation rate, cumulative amount 
of release and cumulative ratio of release compared to 
oleic acid and propylene glycol (p<0.05) (Figure 6). The 
fastest rate of permeation in the case of urea was explained 
by it having the lowest molecular weight when compared 
to the more lipophilic penetrations (Table II), as well as 
by its permeation-enhancing potential for the hydrophilic 
drugs because the value of logP of ISDN was 0.95, as 
calculated using Advanced Chemistry Development 
(ACD/Labs) Software V 11.02 (Ochalek et al., 2012). 
Actually, the excised animal skin could not represent 
the real permeation of drugs transporting through 
human skin. But, the animal skin is frequently used as 
a replacement for human skin, because the human skin 
is difficult to acquire under ethical principles. Schmook 
et al (2001) compared the penetration properties of 
human skin with animal (pig and rat) skin for four topical 
dermatological drugs (salicylic acid, hydrocortisone, 
clotrimazole and terbinafine) with widely varying 
polarity. The results revealed that the order of permeation 
rates was rat > pig > human (terbinafine), rat > pig ~ 
human (clotrimazole), rat>human>pig (hydrocortisone), 
rat>human>pig (salicylic acid). Thus, we could surmise 
the permeation rates of the drug transporting through the 
human skin would be less than the values of rat skin. 
Effect of the pressure sensitive adhesive on the 
permeation
When PVA was used as the drug reservoir, urea 
was used as the penetration enhancer and M1 was used 
as the rate-controlling membrane, the in vitro release 
behaviour of the PSA through the rats’ ex-vivo skin was 
studied. Comparing the values of the permeation rates of 
formulation groups F5 and F6, it was found that the value 
of Jss showed a significant decrease when the PSA was 
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TABLE IV - Comparison of the p values from the permeation 
rates in four formulation groups
Comparison formulation groups p value
F2 F3 0.33
F4 0.38
F5 0.24
F3 F4 0.75
F5 0.62
F4 F5 0.41
FIGURE 6 - In vitro release of ISDN in four formulations with 
different penetration enhancers across through the rats’ ex-vivo 
skin. 
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TABLE V - In vitro release of formulations with different pressure sensitive adhesives
Formulation PSA Jss 
(μg/cm2/h)
Cumulative amount 
of release at 48 h 
(μg)
Correlation factor 
(r2)
Cumulative ratio of 
release at 48 h (%)
F5 - 24.4 ± 0.1 1045.7 ± 19.5 0.9974 42.8 ± 1.1
F6 PSA without ISDN 16.7 ± 0.7 713.5 ± 35.4 0.9937 28.9 ± 1.2
F7 PSA with ISDN 19.9 ± 0.2 861.4 ± 3.3 0.9972 34.9 ± 0.5
Controlling group 19.0 ± 0.6 852.9 ± 9.6 0.9945 89.8 ± 1.0
used in the formulation (p<0.05). To increase the value of 
Jss, 5% (w/w) ISDN was added into the PSA, as shown in 
formulation F7, and promotion effects of permeation were 
observed in formulation F7 compared with formulation F6 
(p<0.05) (Table V).
Pharmaceutical equivalent evaluation
Commercially available Frandol® Tape was used a 
controlling group. Comparing in vitro releasing behavior 
of formulation group F7 and Frandol® Tape, it was found 
that both groups could control drug release at a sustained 
rate for up to 48 h. There were no significant differences 
in the permeation rates between formulation F7 and the 
controlling group (p>0.05). The cumulative release ratio 
at 48 h of the developed patch was only 34.9%, but up to 
89.8% in the Frandol® Tape (Figure 7), which meant that 
the developed patch would release at a constant rate for a 
longer time than the controlling group. The reason for the 
significant difference in cumulative release ratio of the two 
patches was that the amount of ISDN in the developed patch 
was up to 3 mg/cm2 but in the Frandol® Tape it was only 
1 mg/cm2. In comparison with Frandol® Tape, which was 
a single-layer adhesive-type patch, the developed reservoir-
type patch showed advantages, whereby the permeation 
rates were controlled by the rate-controlling membrane and 
the drug-release time was decided by the amount of drugs 
in the reservoir layer. Thus, it was easy to tune the release 
rate and release time to achieve the prediction. 
Physical evaluation of optimised patches
The optimised formulation, F7, with an area of 1 cm2 
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FIGURE 7 – Comparison release of the developed patch with 
the controlling group. 
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HALINA, G.; KRZYSZTOF, C.; STANISLAW, J. Effect of 
penetration enhancers on isosorbide dinitrate penetration 
through rat skin from a transdermal therapeutic system. Int. 
J. Pharm., v.199, n.1, p.1-6, 2000.
JOHNSON, K.I.; GLADIGAU, v.; SCHNELLE, K. Relationship 
between the pharmacodynamics and pharmacokinetics of 
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NG, S.W.; ROUSE, J.J.; SANDERSON, F.D.; MEIDAN, 
v.; ECCLESTON, G.M. Validation of a static Franz 
diffusion cell system for in vitro permeation studies. Aaps 
Pharmscitech, v. 11, n.3, p.1432-1441, 2010.
OCHALEK, M.; PODHAISKY, H.; RUETTINGER, H.H.; 
NEUBERT, R.H.H.; WOHLRAB, J. SC lipid model 
membranes designed for studying impact of ceramide 
species on drug diffusion and permeation, Part III: Influence 
of penetration enhancer on diffusion and permeation of 
model drugs. Int. J. Pharm., v.436, n.1-2, p.206-213, 2012.
PRAUSNITZ, M.R.; LANGER, R. Transdermal drug delivery. 
Nat. Biotechnol., v.26, n.11, p.1261-1268, 2008.
SCHMOOK, F.P. ; MEINGASSNER, J.G.; BILLICH, A. 
Comparison of human skin or epidermis models with human 
and animal skin in in-vitro percutaneous absorption. Int. J. 
Pharm., v.215, n.1-2, p.51-56, 2001.
SHEN, T.; XU, H.; WENG, W.; ZHANG, J. Development of 
a reservoir-type transdermal delivery system containing 
eucalyptus oil for tetramethylpyrazine. Drug Deliv., v.20, 
n.1, p.19-24, 2013.
SUBEDI, R.K.; OH,S. Y.; CHUN, M.K.; CHOI, H.K. Recent 
advances in transdermal drug delivery. Arch. Pharm. Res., 
v.33, n.3, p.339-351, 2010.
TAN, H.S.; PFISTER, W.R. Pressure-sensitive adhesives for 
transdermal drug delivery systems. Pharm. Sci. Technol. 
Today, v.2, n.2, p.60-69, 1999.
was tested for various physical parameters. The thickness 
of formulation F7 was found to be 256.4±11.8 μm. The 
weight of formulation F7 was 43.7±1.3 mg. The drug 
content in formulation F7 was 2954.7±20.3 mg. Compared 
to the calculated drug content of 3 mg/cm2, the percent 
loss of drug in the preparation process was below 2%. 
The results indicated that the reservoir-type transdermal 
patch of ISDN developed in this study possessed uniform 
thickness, weight and drug content.
CONCLUSION
A reservoir-type transdermal patch of ISDN 
was prepared in this paper. The developed patch was 
fabricated by a temporary liner, an adhesive layer, a 
rate-controlling membrane, a reservoir and a backing. 
In the developed patch, the optimised drug reservoir 
included 75% PVA, 10% ISDN and 5% urea; the 
optimised rate-controlling membrane was synthesised 
by 2-hydroxy-3-phenoxypropylacrylate, 4-hydroxybutyl 
acrylate and diethyl maleate; the optimised PSA was 5% 
ISDN dispersed in the mixture of PVP K90, PEG400 
and gelatine. Compared with the commercial patch, 
the developed patch presented a longer release time 
at a sustained release rate and would promote patient 
satisfaction. Such a reservoir-type transdermal patch had 
more advantages over the adhesive-type patch, including 
sustained release rate, owing to the rate-controlling 
membrane, and a higher loading-drug amount, owing to 
the separated drug reservoir layer. Thus, it was easy to 
tune release rate and release time to achieve the prediction. 
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